ORGANOGENESIS HOLDINGS INC (ORGO) Fundamental Analysis & Valuation

NASDAQ:ORGO • US68621F1021

Current stock price

2.47 USD
+0.08 (+3.35%)
At close:
2.47 USD
0 (0%)
After Hours:

This ORGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ORGO Profitability Analysis

1.1 Basic Checks

  • ORGO had positive earnings in the past year.
  • ORGO had a negative operating cash flow in the past year.
  • Of the past 5 years ORGO 4 years were profitable.
  • ORGO had a positive operating cash flow in 4 of the past 5 years.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • ORGO has a Return On Assets of 2.65%. This is amongst the best in the industry. ORGO outperforms 88.82% of its industry peers.
  • ORGO's Return On Equity of 3.65% is amongst the best of the industry. ORGO outperforms 89.79% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.83%, ORGO belongs to the best of the industry, outperforming 92.49% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 18.95%.
  • The 3 year average ROIC (5.16%) for ORGO is below the current ROIC(8.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROIC 8.83%
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • ORGO's Profit Margin of 2.81% is amongst the best of the industry. ORGO outperforms 88.44% of its industry peers.
  • In the last couple of years the Profit Margin of ORGO has declined.
  • The Operating Margin of ORGO (9.90%) is better than 90.37% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has grown nicely.
  • ORGO has a better Gross Margin (75.62%) than 83.43% of its industry peers.
  • ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

4

2. ORGO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ORGO is destroying value.
  • Compared to 1 year ago, ORGO has more shares outstanding
  • Compared to 5 years ago, ORGO has less shares outstanding
  • Compared to 1 year ago, ORGO has a worse debt to assets ratio.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ORGO has an Altman-Z score of 2.89. This is not the best score and indicates that ORGO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ORGO (2.89) is better than 67.63% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that ORGO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.03, ORGO is in line with its industry, outperforming 44.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 2.89
ROIC/WACC0.96
WACC9.23%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • ORGO has a Current Ratio of 3.62. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.62, ORGO perfoms like the industry average, outperforming 43.55% of the companies in the same industry.
  • ORGO has a Quick Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.32, ORGO is in line with its industry, outperforming 41.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.32
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

5

3. ORGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.94% over the past year.
  • The Earnings Per Share has been growing by 16.72% on average over the past years. This is quite good.
  • The Revenue has grown by 17.04% in the past year. This is quite good.
  • The Revenue has been growing by 10.77% on average over the past years. This is quite good.
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%

3.2 Future

  • ORGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.92% yearly.
  • The Revenue is expected to decrease by -0.44% on average over the next years.
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-21.5%
Revenue Next 2Y-0.44%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

4

4. ORGO Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.50, the valuation of ORGO can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 96.92% of the companies listed in the same industry.
  • ORGO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.54.
  • ORGO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 9.5
Fwd PE N/A
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 98.84% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.17
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The decent profitability rating of ORGO may justify a higher PE ratio.
  • A more expensive valuation may be justified as ORGO's earnings are expected to grow with 12.92% in the coming years.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y12.92%
EPS Next 3YN/A

0

5. ORGO Dividend Analysis

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ORGO Fundamentals: All Metrics, Ratios and Statistics

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (3/23/2026, 8:12:11 PM)

After market: 2.47 0 (0%)

2.47

+0.08 (+3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners54.15%
Inst Owner Change-0.51%
Ins Owners32.49%
Ins Owner Change1.24%
Market Cap317.74M
Revenue(TTM)564.17M
Net Income(TTM)15.85M
Analysts85
Price Target8.67 (251.01%)
Short Float %18.72%
Short Ratio16.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)106.05%
Min EPS beat(2)44.72%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)16.53%
Min EPS beat(4)-73%
Max EPS beat(4)167.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.19%
Min Revenue beat(2)10.3%
Max Revenue beat(2)28.08%
Revenue beat(4)2
Avg Revenue beat(4)6.94%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)28.08%
Revenue beat(8)6
Avg Revenue beat(8)7.04%
Revenue beat(12)7
Avg Revenue beat(12)4.32%
Revenue beat(16)7
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-244.44%
EPS NQ rev (3m)-244.44%
EPS NY rev (1m)-117.24%
EPS NY rev (3m)-117.24%
Revenue NQ rev (1m)-56.57%
Revenue NQ rev (3m)-56.57%
Revenue NY rev (1m)-26.17%
Revenue NY rev (3m)-26.17%
Valuation
Industry RankSector Rank
PE 9.5
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.8
EV/EBITDA 3.17
EPS(TTM)0.26
EY10.53%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.39
BVpS3.37
TBVpS3.08
PEG (NY)N/A
PEG (5Y)0.57
Graham Number4.44
Profitability
Industry RankSector Rank
ROA 2.65%
ROE 3.65%
ROCE 11.21%
ROIC 8.83%
ROICexc 10.88%
ROICexgc 12%
OM 9.9%
PM (TTM) 2.81%
GM 75.62%
FCFM N/A
ROA(3y)1.41%
ROA(5y)5.82%
ROE(3y)2.05%
ROE(5y)10.24%
ROIC(3y)5.16%
ROIC(5y)7.22%
ROICexc(3y)6.81%
ROICexc(5y)10.02%
ROICexgc(3y)7.75%
ROICexgc(5y)12.19%
ROCE(3y)6.54%
ROCE(5y)9.15%
ROICexgc growth 3Y14.91%
ROICexgc growth 5Y-14%
ROICexc growth 3Y18.93%
ROICexc growth 5Y-6.02%
OM growth 3Y26.04%
OM growth 5Y4.64%
PM growth 3Y1.07%
PM growth 5Y-6.94%
GM growth 3Y-0.48%
GM growth 5Y0.38%
F-Score2
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.17
Cap/Depr 76.1%
Cap/Sales 2.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.32
Altman-Z 2.89
F-Score2
WACC9.23%
ROIC/WACC0.96
Cap/Depr(3y)97.86%
Cap/Depr(5y)180.1%
Cap/Sales(3y)3.4%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.94%
EPS 3Y25.99%
EPS 5Y16.72%
EPS Q2Q%416.67%
EPS Next Y-109.81%
EPS Next 2Y12.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.04%
Revenue growth 3Y7.76%
Revenue growth 5Y10.77%
Sales Q2Q%78.13%
Revenue Next Year-21.5%
Revenue Next 2Y-0.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y159.64%
EBIT growth 3Y35.82%
EBIT growth 5Y15.91%
EBIT Next Year-3.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-685.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.56%
OCF growth 3YN/A
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 7 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 4 / 10.